---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-014293"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-09-19T23:59:59+00:00"
generated_at: "2026-05-17T06:08:59.399724+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Calidi eliminates CLO role; W. Pizarro Campbell departs Oct 17, 2025

## Summary
- CLO position eliminated; Campbell's employment terminated Oct 17, 2025 as part of cost-reduction initiatives; no disagreement cited.
- Campbell receives severance of $212,500 paid over six months, plus potential $85,000 bonus tied to Nova Cell transaction before Oct 31, 2025.
- Campbell enters six-month consulting agreement at $250/hr (max 20 hrs/mo) starting Oct 18, 2025.
- CFO Andrew Jackson appointed as Corporate Secretary effective Oct 17, 2025.
- Separation agreement includes standard release, confidentiality, and non-disparagement clauses.

## SEC filing metadata
- accession: 0001493152-25-014293
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-09-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315225014293/0001493152-25-014293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315225014293/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-014293
- JSON: https://secwatch.observer/filing/0001493152-25-014293.json
- Plain text: https://secwatch.observer/filing/0001493152-25-014293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.